Company: VRCA
Filing Date: 2025-04-22
Form Type: DEF 14A
Source: 0001193125-25-087838
Chunk: 62

Company: Verrica Pharmaceuticals Inc.
Filing Date: 2025-04-22
Form: DEF 14A
Chunk 62
---
2 |
| Christopher G. Hayes |     |            |     | 10/09/2024 |     |                      |     |    50,000 |     |           |     |   1.28 |     |            |     |    50,500 |     |                                |     | 0%(3)      |

| (1) | The amounts reflect the full grant date fair value, computed in accordance with ASC Topic 718. Consistent with the calculations contained in our financial statements, this calculation does not give effect to any estimate of forfeitures related to service-based vesting, but assumes that the executive will perform the requisite service for the award to vest in full. The assumptions we used in valuing options are described in Note 8 to our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2024. |

| (2) | We filed our Quarterly Report on Form 10-Q for the quarter ended September 30, 2024 pre-market on November 5, 2024. The closing stock price per share of our common stock on November 4, 2024 and November 6, 2024 was $1.43 and $0.7463, respectively. |

| (3) | We filed a Current Report on Form 8-K after market close on October 8, 2024. The closing stock price per share of our common on each of October 8, 2024 and October 9, 2024 was $1.28. |

48

SECURITIES AUTHORIZED FOR ISSUANCE UNDER EQUITY COMPENSATION PLANS The following table shows information regarding our equity compensation plans as of December 31, 2024:

| Name                                                          |     | Number of        
 securities to be 
 issued upon      
 exercise of      
 outstanding      
 options,         
 warrants and     
 rights(a)        |           |    |     | Weighted- average 
 exercise price    
 of outstanding    
 options,          
 warrants and      
 rights(b)         
 ($)               |      |    |     | Number of securities  
 remaining available   
 for future issuance   
 under equity          
 compensation plans    
 (excluding securities 
 reflected in          
 column (a))(c)        |           |    |
| Equity compensation plans approved by security holders        |     |                  | 5,439,887 | -1 |     |                   | 5.35 | -2 |     |                       | 4,